PUBLICATION
The apatinib and pemetrexed combination has antitumor and antiangiogenic effects against NSCLC
- Authors
- Zhou, L., Zhang, W., Xiang, Y., Qian, Z., Zhou, J., Ni, L., Feng, Y., Gao, B.
- ID
- ZDB-PUB-230314-34
- Date
- 2023
- Source
- Open life sciences 18: 2022053320220533 (Journal)
- Registered Authors
- Keywords
- NSCLC, apatinib, pemetrexed, zebrafish model
- MeSH Terms
- none
- PubMed
- 36910471 Full text @ Open Life Sci
Citation
Zhou, L., Zhang, W., Xiang, Y., Qian, Z., Zhou, J., Ni, L., Feng, Y., Gao, B. (2023) The apatinib and pemetrexed combination has antitumor and antiangiogenic effects against NSCLC. Open life sciences. 18:2022053320220533.
Abstract
Chemotherapy for advanced non-small-cell lung cancer (NSCLC) remains the first treatment choice. Angiogenesis inhibitors are effective for lung cancer treatment. This study explored whether chemotherapy combined with angiogenesis inhibitors could achieve better efficacy in NSCLC. The zebrafish A549 xenograft model was used to investigate the combined effect of apatinib and chemotherapeutic agents in NSCLC. Apatinib combined with pemetrexed demonstrated the highest antitumor effect compared with apatinib combined with gemcitabine or paclitaxel in vitro. In the zebrafish A549 xenograft model, apatinib and pemetrexed, alone or in combination, showed significant inhibition of tumor growth. Co-treatment with apatinib and pemetrexed demonstrated the best antitumor effects, suggesting that the combination of apatinib and pemetrexed might be a promising alternative therapy for patients with lung cancer. Apatinib combined with pemetrexed had enhanced antitumor effects compared with either one alone in the zebrafish model of NSCLC.
Genes / Markers
Expression
Phenotype
Mutations / Transgenics
Human Disease / Model
Sequence Targeting Reagents
Fish
Orthology
Engineered Foreign Genes
Mapping